Search research articles
Contact Us
Filters
Showing results (201-210 of 214) with videos related to
Page
of 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open
|
November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R Gutzmer, L Rivoltini, E Levchenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>
Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
M Kandel, C Allayous, S Dalle, et al.
Allergy
|
March 10, 2011
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper
I Baiardini, F Braido, C Bindslev-Jensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
L Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 214) with videos related to
Sort By:
Page
of 22
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
ESMO Open
|
November 16, 2016
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
R Gutzmer, L Rivoltini, E Levchenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>
Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
M Kandel, C Allayous, S Dalle, et al.
Allergy
|
March 10, 2011
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper
I Baiardini, F Braido, C Bindslev-Jensen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
L Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Page
of 22